New Delhi, March 10 (IANS). In FY 2026, the Indian Pharma market is expected to increase by 8-9 percent on an annual basis. This information was given in a latest report released on Monday.
The report of India Ratings and Research (IND-RA) states that the increase of this sector in FY 2025 will be 7.5-8.0 percent on an annual basis.
Krishnath Munde, Associate Director of India Ratings and Research, said that “the Indian Pharma market had an increase of 6.5 percent annually in FY 2024 and 9.9 percent on an annual basis in FY 2023.”
In February this year, Pharma Bazar gave a revenue of 7.5 percent on an annual basis. The report said that this price and new launch were seen due to increase in the new launch. Price hikes increased by 5.2 percent on an annual basis and 2.4 percent on the new launch on an annual basis.
The report stated that in addition, the 12 -month rolling sales of Moving Annual Total (MAT) or overall pharma products saw an increase of 8.1 percent in February.
Cardiac therapy performed better with an increase of 10.8 percent in MAT in Pharma market and 13.7 percent increase in monthly market share.
This was followed by gastroenterology, neurology/central nervous system and dermatology.
The report stated that on the other hand, anti-infactive, respiratory and gynecology therapy saw a weak increase in February.
Meanwhile, a second recent report showed that there is a rapid production increase in the pharma sector in the country.
According to the report of McKinse & Co., the Indian Pharma Sector has increased from 8 percent CAGR and 2024 has also seen an increase of 9 percent in export rates.
Expanding its abilities in API and biotechnology, it has increased by 8 percent of CAGR, which is twice the global average.
The report said that the country has also become the world’s largest supplier of generic drugs, whose pharma export growth rate is 9 percent, which is almost double the global average.
-IANS
SKT/ABM
